Eton Pharmaceuticals, Inc. (ETON) – What Are Analysts Saying About This Stock?

Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) have received a consensus rating of “Buy” from the six brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $71.50.

Several equities research analysts recently commented on the stock. B. Riley Financial reiterated a “buy” rating and issued a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a research report on Friday, August 14th. Weiss Ratings upgraded shares of Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. Craig Hallum restated a “buy” rating and set a $78.00 target price on shares of Eton Pharmaceuticals in a report on Thursday, October 15th. Canaccord Genuity Group lifted their target price on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a research report on Friday, August 14th. Finally, Zacks Research raised shares of Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 12th.

Insider Activity at Eton Pharmaceuticals

In other news, insider David Krempa sold 4,166 shares of the firm’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $55.07, for a total transaction of $229,421.62. Following the completion of the transaction, the insider directly owned 43,381 shares of the company’s stock, valued at $2,388,991.67. This trade represents a 8.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Paul V. Maier sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the transaction, the director directly owned 59,745 shares of the company’s stock, valued at approximately $3,529,137.15. This trade represents a 45.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 79,166 shares of company stock worth $4,809,672 over the last quarter. Company insiders own 16.49% of the company’s stock.

Hedge Funds Weigh In On Eton Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Hsbc Holdings PLC purchased a new stake in shares of Eton Pharmaceuticals in the second quarter valued at $1,531,000. Bank of New York Mellon Corp purchased a new stake in Eton Pharmaceuticals during the 2nd quarter worth about $4,281,000. Squarepoint Ops LLC purchased a new stake in Eton Pharmaceuticals during the 2nd quarter worth about $2,156,000. Jefferies Financial Group Inc. purchased a new stake in Eton Pharmaceuticals during the 2nd quarter worth about $1,232,000. Finally, Bank of Nova Scotia purchased a new stake in Eton Pharmaceuticals during the 2nd quarter worth about $623,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Stock Up 0.3%

ETON opened at $50.17 on Tuesday. The business’s fifty day moving average is $56.76 and its two-hundred day moving average is $34.84. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.30 and a current ratio of 1.52. The company has a market cap of $1.43 billion, a price-to-earnings ratio of 132.03 and a beta of 0.90. Eton Pharmaceuticals has a one year low of $14.27 and a one year high of $66.37.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Thursday, August 13th. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.24. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. The company had revenue of $37.59 million for the quarter, compared to analyst estimates of $27.11 million. Analysts anticipate that Eton Pharmaceuticals will post 1.13 EPS for the current fiscal year.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.